Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,000Price:$0.84
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 06, 2024 (filed on Mar 06, 2024)Insider Name:Bobulsky SusanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
Filings by filing date
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,000Price:$0.84
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Pellini Michael JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,044Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Pellini Michael JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,328Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Owen Katey EinterzOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,044Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Owen Katey EinterzOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,328Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,044Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,328Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Hershberg RobertOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,044Price:--
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Hershberg RobertOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,328Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1165 Eastlake Ave E SEATTLE WA 98109 |
Tel: | 1-650-8251656 |
Website: | https://www.adaptivebiotech.com |
IR: | See website |
Key People | ||
Chad M. Robins Chairman of the Board, Chief Executive Officer, Co-Founder | Julie Rubinstein President, Chief Operating Officer | Harlan S. Robins Co-Founder, Chief Scientific Officer |
Kyle Piskel Chief Financial Officer | Francis Lo Chief People Officer | Stacy Taylor Senior Vice President, General Counsel, Corporate Secretary | Sharon Benzeno Chief Commercial Office - Immune Medicine |
Business Overview |
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient's immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma). |
Financial Overview |
For the fiscal year ended 31 December 2023, Adaptive Biotechnologies Corp revenues decreased 8% to $170.3M. Net loss increased 13% to $225.3M. Revenues reflect Immune meidicine revenue segment decrease of 31% to $67.5M. Higher net loss reflects Interest Expense increase from $4.2M to $13.8M (expense), Personnel expenses increase of 9% to $74.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.40 to -$1.56. |
Employees: | 709 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $27.94M as of Dec 31, 2023 |
Annual revenue (TTM): | $170.28M as of Dec 31, 2023 |
EBITDA (TTM): | -$179.38M as of Dec 31, 2023 |
Net annual income (TTM): | -$225.25M as of Dec 31, 2023 |
Free cash flow (TTM): | -$167.02M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 145,092,271 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |